Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
Text Size

Cone Beam CT Scanning in Lung and Bladder Cancer.

This study has been completed.
Sponsor:
Collaborator:
Cross Cancer Institute
Information provided by (Responsible Party):
AHS Cancer Control Alberta
ClinicalTrials.gov Identifier:
NCT00469066
First received: May 2, 2007
Last updated: February 23, 2016
Last verified: December 2011
History of Changes
  Purpose
To study changes in tumor and normal organ size and/or position which occur during a course of radiation treatments.

Condition
Lung Neoplasm
Small Cell Carcinoma
Bladder Carcinoma

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Improving the Accuracy of Radiotherapy Planning and Delivery Using Kilovoltage Cone Beam CT Imaging

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by AHS Cancer Control Alberta:
Enrollment: 22
Study Start Date: May 2007
Study Completion Date: April 2010
Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
  Eligibility
Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
primary care clniic
Criteria

Inclusion Criteria:

  • Patient has biopsy proven limited stage SCLC
  • receiving radical concurrent chemoradiotherapy
  • no prior chest RT
  • no prior surgical resection of lung tumor
  • no prior chemotherapy
  • patients' lung tumors should be centrally-located to minimize the effect of respiratory motion
  • patient has biopsy proven TCC bladder
  • receiving radical concurrent chemoradiotherapy or RT alone
  • no prior chemotherapy
  • patient signs study-specific consent form

Exclusion Criteria:

  • mixed small cell and non small cell histology
  • patient not being treated with concurrent chemoradiotherapy
  • chemoradiotherapy given sequentially
  • previous chest RT
  • previous chemotherapy
  • prior surgical resection of lung mass
  • patient ineligible for pelvic RT
  • patient does not sign study consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00469066

Locations
Canada, Alberta
Cross Cancer Institute
Edmonton, Alberta, Canada
Sponsors and Collaborators
AHS Cancer Control Alberta
Cross Cancer Institute
Investigators
Principal Investigator: Don Yee, MD AHS Cancer Control Alberta
  More Information

Responsible Party: AHS Cancer Control Alberta
ClinicalTrials.gov Identifier: NCT00469066     History of Changes
Other Study ID Numbers: LU-11-0073 
Study First Received: May 2, 2007
Last Updated: February 23, 2016
Health Authority: Canada: Health Canada

Keywords provided by AHS Cancer Control Alberta:
small cell lung cancer
bladder cancer
conformal radiotherapy

Additional relevant MeSH terms:
Carcinoma
Lung Neoplasms
Carcinoma, Small Cell
Small Cell Lung Carcinoma
Urinary Bladder Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
 Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Urinary Bladder Diseases
Urologic Diseases

ClinicalTrials.gov processed this record on September 28, 2016